Management of hepatocellular carcinoma from diagnosis in routine clinical practice

To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire av...

Full description

Saved in:
Bibliographic Details
Published in:Hepatic oncology 2022-12, Vol.9 (4), p.HEP45-HEP45
Main Authors: Lokhandwala, Tasneem, Aly, Abdalla, Farrelly, Eileen, Willey, Joanne P, Lamerato, Lois E, Healey, Marcus, Coutinho, Anna D, Seal, Brian S
Format: Article
Language:English
Subjects:
Child-Pugh class
hepatocellular carcinoma
liver resection/excision
liver transplantation
locoregional therapies
overall survival
radiofrequency ablation
Short Communication
transarterial chemoembolization
transarterial radioembolization
treatment journey
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient. Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72–82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy. This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.
ISSN:2045-0923
2045-0931
DOI:10.2217/hep-2021-0011